Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Major inclusion criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2~* Pathologically confirmed relapsed/refractory DLBCL~* Subjects must have ≥1 measurable disease site on CT scan (≥ 1.5 cm in longest dimension).~* Adequate hepatic and renal function:~  * AST or ALT ≤2.5 x ULN~ * Serum Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥60 mL/min/1.73~ * Bilirubin ≤1.5 x ULN~* Adequate hematologic function:~  * ANC \>1,000 cells/mm3~ * Platelets ≥75,000 cells/mm3~ * Hemoglobin ≥8.0 g/dL~ * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be ≤1.5 x the upper limit of the normal range (ULN)~* Must be registered into the Revlimid REMS™program and be willing to comply with the requirements of Revlimid REMS™.~Major Exclusion Criteria:~* Known central nervous system lymphoma~* Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks~* Radio- or toxin-immunoconjugates within 10 weeks~* Prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Dose Level 1 (Type: EXPERIMENTAL): Ibrutinib 560 mg PO + DA-EPOCH-R
- Part 1: Dose Level 2 (Type: EXPERIMENTAL): Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
- Part 1: Dose Level 3 (Type: EXPERIMENTAL): Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
- Part 1: Dose Level 4 (Type: EXPERIMENTAL): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
- Part 2: RP2D (Type: EXPERIMENTAL): Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R

Based on this trial design, predict the completion outcome and termination type (if applicable).